HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $70.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 416.99% from the company’s current price.

Several other brokerages have also recently weighed in on QURE. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Wells Fargo & Company dropped their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. StockNews.com raised uniQure to a “sell” rating in a research report on Tuesday, March 11th. Finally, Chardan Capital assumed coverage on uniQure in a research report on Tuesday, April 1st. They set a “buy” rating and a $38.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.80.

uniQure Trading Up 4.2 %

uniQure stock traded up $0.54 during trading hours on Monday, hitting $13.54. The company had a trading volume of 3,297,138 shares, compared to its average volume of 1,755,236. The company has a 50-day moving average price of $11.89 and a two-hundred day moving average price of $11.33. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The firm has a market cap of $732.20 million, a P/E ratio of -2.73 and a beta of 0.42.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now owns 580,795 shares of the company’s stock, valued at approximately $6,574,599.40. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 14,341 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the sale, the chief financial officer now directly owns 152,372 shares of the company’s stock, valued at $1,630,380.40. This represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 90,830 shares of company stock worth $961,401. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of QURE. Avoro Capital Advisors LLC purchased a new stake in uniQure in the 4th quarter valued at $38,410,000. Franklin Resources Inc. boosted its position in shares of uniQure by 33.1% during the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock valued at $35,103,000 after acquiring an additional 494,726 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of uniQure by 81.3% in the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after purchasing an additional 794,459 shares during the period. Integral Health Asset Management LLC increased its position in uniQure by 175.0% during the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $19,426,000 after purchasing an additional 700,000 shares during the last quarter. Finally, RTW Investments LP raised its stake in uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after purchasing an additional 893,625 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.